LogiMAT 2027 in Stuttgart

LogiMAT bleibt vorerst bis 2031 in Stuttgart

EUROEXPO und Messe Stuttgart verlängern langjährige Zusammenarbeit / Standort Stuttgart für weitere fünf Jahre bestätigt

Die EUROEXPO Messe- und Kongress-GmbH und die Messe Stuttgart haben ihre langjährige Partnerschaft um weitere fünf Jahre verlängert. Damit bleibt die LogiMAT, eine der international bedeutendsten Fachmessen für Intralogistik-Lösungen und Prozessmanagement, bis mindestens 2031 am Standort Stuttgart. 

Die Vereinbarung unterstreicht die Bedeutung der LogiMAT für die Logistikbranche und für den Messestandort Stuttgart. Seit ihrer Premiere im Jahr 2003 hat sich die Veranstaltung kontinuierlich weiterentwickelt. Heute bringt sie Unternehmen aus der gesamten Wertschöpfungskette der Intralogistik mit Fachbesucherinnen und Fachbesuchern aus Industrie, Handel und Dienstleistungswirtschaft zusammen. Im Mittelpunkt stehen aktuelle Lösungen und Technologien für effiziente, vernetzte und zukunftsfähige Logistikprozesse. Im Jahr 2027 feiert die LogiMAT am Standort Stuttgart ihr 25. Jubiläum.

„Die LogiMAT ist eine der wichtigsten Veranstaltungen in unserem Portfolio. Wir freuen uns deshalb sehr, die erfolgreiche Zusammenarbeit mit der Messe Stuttgart fortsetzen zu können und der Branche auch künftig eine leistungsfähige Plattform zu bieten“, sagt Christoph Huss, Geschäftsführer der EUROEXPO Messe- und Kongress-GmbH. „Der Standort Stuttgart bietet dafür hervorragende Voraussetzungen – sowohl mit seiner modernen Infrastruktur, als auch durch seine ausgezeichnete Erreichbarkeit und die Nähe zu zahlreichen bedeutenden Industrie- und Technologiestandorten.“

Michael Ruchty, Messeleiter der LogiMAT in Stuttgart, ergänzt: „Die LogiMAT lebt vom engen Austausch zwischen den ausstellenden Unternehmen, Fachbesucherinnen und Fachbesuchern sowie den zahlreichen Branchenexpertinnen und -experten. Unser Anspruch ist es, die LogiMAT in den kommenden Jahren kontinuierlich weiterzuentwickeln und ihren Stellenwert als führende Plattform für Innovationen, Trends und konkrete Lösungen entlang der logistischen Prozesskette weiter auszubauen.“

LogiMAT 2026 erzielt Spitzenwerte

Wie groß die Bedeutung der LogiMAT inzwischen ist, zeigte die Veranstaltung im März 2026. Die Messe erzielte nach Angaben der EUROEXPO neue Spitzenwerte bei der Zahl der ausstellenden Unternehmen, der Nettoausstellungsfläche, dem Internationalisierungsgrad sowie bei den Fachbesucherzahlen. An den drei Messetagen kamen insgesamt 69.856 Fachbesucherinnen und Fachbesucher auf das Stuttgarter Messegelände.

Damit bestätigte die LogiMAT ihre Rolle als zentraler Branchentreffpunkt für die internationale Logistik- und Intralogistikindustrie. Die Veranstaltung schafft Raum für den persönlichen Austausch, die Präsentation neuer Technologien und den Wissenstransfer zu Themen, die Unternehmen aktuell besonders beschäftigen – darunter die weitere Digitalisierung von Logistikprozessen, Automatisierung, effiziente Materialflüsse und die steigenden Anforderungen an resiliente Lieferketten.

„Die verlängerte Zusammenarbeit mit EUROEXPO ist ein starkes Zeichen für das Vertrauen und den gemeinsamen Erfolg, den wir in den vergangenen Jahrzehnten in Stuttgart erreicht haben. Auch die internationale Zusammenarbeit rund um die LogiMAT China zeigt, wie erfolgreich sich die Partnerschaft entwickelt hat“, sagt Stefan Lohnert, Geschäftsführer der Messe Stuttgart. „Die LogiMAT hat sich als wichtiger Treffpunkt für die Logistikbranche etabliert. Wir sind stolz darauf, diese wegweisende Veranstaltung gemeinsam mit unserem Partner weiterhin am Messeplatz Stuttgart zu gestalten und ihre Entwicklung aktiv zu begleiten.“

Für die Messe Stuttgart ist die Verlängerung zugleich eine Bestätigung ihrer Position als leistungsfähiger Standort für internationale Fachmessen mit hoher Branchenrelevanz. Das Messegelände bietet mit seinen multifunktionalen Hallen, der modernen Infrastruktur und der direkten Anbindung an Flughafen, Autobahn und öffentlichen Nahverkehr optimale Bedingungen für eine Veranstaltung von internationaler Reichweite.

Die nächste LogiMAT findet vom 16. bis 18. März 2027 auf dem Stuttgarter Messegelände statt.

4.148 Anschläge inklusive Leerzeichen

Veranstalter: EUROEXPO Messe- und Kongress-GmbH Joseph-Dollinger-Bogen 7, 

80807 München Tel.: +49 (0)89 32391-259 | www.logimat-messe.de

München, den 15.09.2026, Abdruck honorarfrei, Belegexemplar erbeten an EUROEXPO Messe- und Kongress-GmbH, Presse- und Öffentlichkeitsarbeit, 80912 München

Über die LogiMAT

Die LogiMAT, Internationale Fachmesse für Intralogistik-Lösungen und Prozessmanagement, findet vom 16. bis 18 März 2027 auf dem Messegelände Stuttgart direkt am Stuttgarter Flughafen statt. Die LogiMAT gilt als weltweit größte Fachmesse für Intralogistik-Lösungen und wird von der EUROEXPO Messe- und Kongress-GmbH ausgerichtet. Sie bietet einen vollständigen Marktüberblick über alles, was die Intralogistik-Branche von der Beschaffung über die Produktion bis zur Auslieferung bewegt. Internationale Aussteller zeigen innovative Technologien, Produkte, Systeme und Lösungen zur Rationalisierung, Prozessoptimierung und Kostensenkung der innerbetrieblichen logistischen Prozesse. Die Veranstaltung bietet neben der Ausstellung täglich wechselnde Vortragsreihen sowie Live-Events zu den unterschiedlichsten Themen.

Auch international ist die LogiMAT an verschiedenen Standorten am Markt. Nächste Termine:

LogiMAT India, 8. bis 10. Februar 2027, Bombay Convention & Exhibition Centre, Mumbai, India

LogiMAT China, 21. bis 23. April 2027, SZCEC, Shenzhen, China

Über die Messe Stuttgart

Die Messe Stuttgart ist eine der führenden deutschen Messegesellschaften. Mit ihrer ausgezeichneten Infrastruktur und ihrem einzigartigen Standort direkt am Flughafen Stuttgart, am öffentlichen Nahverkehr und an der Autobahn A 8 ist sie ein internationaler Treffpunkt für verschiedene Branchen und Märkte. Das Messegelände umfasst rund 120.000 Quadratmeter Innenfläche und 40.000 Quadratmeter Freifläche und bietet den idealen Rahmen für erfolgreiche Veranstaltungen. Das angeschlossene ICS Internationales Congresscenter Stuttgart ergänzt das Angebot mit 33 flexibel nutzbaren Räumen. Die Messe Stuttgart organisiert auch Messen im In- und Ausland. Mit vier Tochtergesellschaften, rund 20 Auslandsvertretungen und zahlreichen Vertriebspartnern ist sie in über 50 Ländern präsent. Zu den führenden Eigen- und Gastveranstaltungen am Standort Stuttgart gehören unter anderem die CMT, die R+T, die INTERGASTRA, die AMB, die LogiMAT, die VISION sowie die südback.

Bildunterschriften:

Bild Nr. 1: Vertragsunterzeichnung:

Stefan Lohnert, Geschäftsführer der Messe Stuttgart.

Christoph Huss, Geschäftsführer der EUROEXPO Messe- und Kongress-GmbH

Copyright der Bilder aus München: Claudia Döttinger / Messe Stuttgart

Bild Nr. 2 (von links): Weitere Zusammenarbeit - ein Grund zur Freude

Stefan Lohnert, Geschäftsführer der Messe Stuttgart.

Michael Ruchty, Messeleiter der LogiMAT in Stuttgart

Christoph Huss, Geschäftsführer der EUROEXPO Messe- und Kongress-GmbH

Copyright der Bilder aus München: Claudia Döttinger / Messe Stuttgart

Siamo lieti di dare il benvenuto a SAB Imballaggi come nuovo distributore SpotSee per il Nord Italia!

L’esperienza di SAB Imballaggi negli imballaggi su misura, unita agli indicatori SpotSee progettati per monitorare le condizioni di trasporto, dà vita a una solida collaborazione per aiutare i clienti a proteggere i propri prodotti durante le spedizioni.

Insieme, possiamo sviluppare soluzioni per un’ampia gamma di settori e applicazioni: dalle scienze della vita alle spedizioni industriali, dalla produzione automobilistica al trasporto di merci fragili e materiali sensibili. Abbinando imballaggi studiati per ogni prodotto a indicatori che segnalano urti, inclinazioni ed escursioni termiche, possiamo aiutare i clienti a ridurre i danni, migliorare la visibilità sulle condizioni delle spedizioni e prendere decisioni più consapevoli.

I nostri indicatori con codice QR ampliano ulteriormente questa visibilità. Ogni scansione registra le condizioni della spedizione, la data, l’ora e la posizione, generando dati preziosi nei punti chiave della filiera logistica.

Questa collaborazione mette competenze complementari a disposizione dei clienti in Italia, aiutandoli ad affrontare le sfide del trasporto con soluzioni che integrano imballaggio e monitoraggio delle condizioni di spedizione.

Benvenuta nella rete di distributori SpotSee, SAB Imballaggi. Siamo pronti a sviluppare insieme soluzioni efficaci e creare valore per i nostri clienti!

Per acquistare online: https://www.centroimballo.it/

Per maggiori informazioni: https://sabimballaggi.com/

________

We are pleased to welcome SAB Imballaggi as a new SpotSee distributor in Northern Italy.

SAB Imballaggi’s expertise in custom packaging, combined with SpotSee’s condition indicators designed for shipping, creates a strong partnership to help customers protect their products throughout transportation.

Together, we can develop solutions for a broad range of industries and applications, from life sciences and industrial shipping to automotive manufacturing, fragile goods, and sensitive materials. By combining packaging tailored to each product with indicators that reveal shock, tilt, and temperature excursions, we can help customers reduce damage, improve visibility, and make more informed decisions.

Our QR-enabled indicators take that visibility further. Every scan captures shipment condition, time, and location, creating valuable data at key points throughout the supply chain.

This partnership brings complementary expertise closer to customers in Italy, helping them address their shipping challenges with packaging and condition monitoring that work together.

Welcome to the SpotSee distributor network, SAB Imballaggi. We look forward to developing effective solutions and delivering value together!

Online store: https://www.centroimballo.it/

For more information: https://sabimballaggi.com/

MENLO PARK, Calif., Oct. 26, 2026 /PRNewswire/ -- Meta Platforms, Inc. (Nasdaq: META) ("Meta" or the "Company") announced today the pricing of its previously announced concurrent separate underwritten public offerings of (i) 250,000,000 series A depositary shares ("Depositary Shares"), each representing a 1/20th interest in a share of newly issued 6.50% Series A Mandatory Convertible Preferred Stock, par value $0.000006 per share ("Preferred Stock"), at a public offering price of $50 per Depositary Share (the "Depositary Shares Offering") and (ii) $25.0 billion of shares of Class A common stock, par value $0.000006 per share ("Class A Common Stock") offered in connection with the forward sale agreements described below, at a public offering price of $625.00 per share (the "Common Stock Offering" and, together with the Depositary Shares Offering, the "Offerings"). The Common Stock Offering was upsized to $25.0 billion from the previously announced offering size of $22.5 billion.

Meta has granted to the underwriters of the Depositary Shares Offering a 30-day option to purchase up to an additional 37,500,000 Depositary Shares at the public offering price less the applicable underwriting discount, solely to cover over-allotments, if any. The net proceeds from the Depositary Shares Offering will be approximately $12.5 billion (or approximately $14.3 billion if the underwriters exercise in full their over-allotment option to purchase additional Depositary Shares) after deducting the applicable underwriting discount and estimated offering expenses payable by Meta. Meta intends to use the net proceeds from the Depositary Shares Offering for general corporate purposes.

Holders of the Depositary Shares will be entitled to a proportional fractional interest in the rights and preferences of the Preferred Stock, including conversion, dividend, liquidation and voting rights, subject to the provisions of a deposit agreement. The Preferred Stock will accumulate dividends (which may be paid initially in cash or, subject to certain limitations, in shares of Class A Common Stock or in any combination of cash and Class A Common Stock) at a rate per annum equal to 6.50% on the liquidation preference thereof, which is $1,000 per share, payable when, as and if declared by Meta's board of directors (or an authorized committee thereof), on February 15, May 15, August 15 and November 15 of each year, beginning on February 15, 2027 and ending on, and including, August 15, 2029. Unless earlier converted, each outstanding share of Preferred Stock will automatically convert for settlement on or about August 15, 2029, into between 1.3620 and 1.6000 shares of Class A Common Stock (and, correspondingly, each Depositary Share will automatically convert into between 0.0681 and 0.0800 shares of Class A Common Stock), subject to customary anti-dilution adjustments, determined based on the volume-weighted average price of the Class A Common Stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day prior to August 15, 2029 (the "final averaging period"). Notwithstanding the foregoing, upon the issuance of Meta's Class C common stock, par value $0.000006 per share (the "Class C Common Stock") to be established by Meta's Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on October 21, 2026 and satisfaction of certain other conditions, (1) each share of Preferred Stock (and, correspondingly, each Depositary Share) will be convertible into shares of Class C Common Stock for settlement on or about August 15, 2029 in a number not less than the then-current minimum conversion rate nor greater than the then-current maximum conversion rate, determined based on the volume-weighted average price of the Class C Common Stock during the final averaging period, (2) other than during a fundamental change conversion period (as defined in the prospectus supplement relating to the Depositary Shares Offering), at any time after the 50th trading day immediately following the Class C Dividend Trigger Date (as defined in the prospectus supplement relating to the Depositary Shares Offering) and prior to the mandatory conversion settlement date, a holder of 20 Depositary Shares may cause the bank depositary to convert one share of Preferred Stock, on such holder's behalf, into a number of shares of Class C Common Stock equal to the then-current minimum conversion rate and (3) cumulative dividends with respect to the Preferred Stock may be paid in cash or, subject to certain limitations, in shares of Class C Common Stock or in any combination of cash and Class C Common Stock, at the election of Meta. Currently, there is no public market for the Depositary Shares or the Preferred Stock. Meta has applied to list the Depositary Shares on the Nasdaq Global Select Market under the symbol "METAM." The Depositary Shares Offering is expected to close on October 29, 2026, subject to satisfaction of the conditions to closing.

Concurrently with the Depositary Shares Offering, Meta entered into forward sale agreements with Morgan Stanley Capital Services LLC and Goldman Sachs & Co. LLC (the "forward purchasers") initially with respect to an aggregate of 40,000,000 shares of the Class A Common Stock. Upon the issuance of the Class C Common Stock and satisfaction of certain other conditions, Meta expects that such forward sale agreements will reference both the Class A Common Stock and the Class C Common Stock. In connection with these forward sale agreements, the forward purchasers or their respective affiliates are expected to borrow from third parties and have agreed to sell to the underwriters in the Common Stock Offering an aggregate of 40,000,000 shares of the Class A Common Stock. The Common Stock Offering is expected to close on October 29, 2026, subject to satisfaction of the conditions to closing.

Meta has also granted the underwriters of the Common Stock Offering a 30-day option to purchase up to $3.75 billion of additional shares of the Class A Common Stock. If such option is exercised, Meta expects to enter into additional forward sale agreements with each of the forward purchasers in respect of the number of shares of the Class A Common Stock that is subject to the exercise of such option. Meta does not expect to initially receive any proceeds from the sale of shares of Class A Common Stock by the forward purchasers (or their affiliates) in the Common Stock Offering. At an initial forward price of approximately $622.92 per share (which is approximately the price at which the underwriters of the Common Stock Offering have agreed to buy the shares of Class A Common Stock offered thereby), Meta expects to receive net proceeds, before expenses, from the Common Stock Offering of approximately $24.9 billion (or approximately $28.7 billion if the underwriters of the Common Stock Offering exercise in full their option to purchase additional shares of Class A Common Stock), subject to the price adjustment and other provisions of the forward sale agreements, upon settlement of the forward sale agreements, which Meta expects to occur on or prior to November 19, 2027. Meta intends to use the net proceeds it receives upon future settlement of the forward sale agreements and any additional forward sale agreements for general corporate purposes.

Pursuant to the terms of the forward sale agreements and any additional forward sale agreements, Meta intends to issue and deliver, upon settlement of the forward sale agreements or any additional forward sale agreements, on one or more dates specified by Meta on or prior to November 19, 2027, an aggregate of 40,000,000 shares of Class A Common Stock (or an aggregate of 46,000,000 shares of Class A Common Stock if the underwriters exercise their option to purchase additional shares in full and if Meta enters into additional forward sale agreements with respect to such shares) to the forward purchasers in exchange for cash proceeds per share equal to the applicable forward sale price, which will be approximately $622.92, subject to certain adjustments as provided in the forward sale agreements and any additional forward sale agreements. Notwithstanding the foregoing, upon the issuance of the Class C Common Stock and satisfaction of certain other conditions, these forward sale agreements will reference both the Class A Common Stock and the Class C Common Stock and, in certain circumstances, Meta will have the ability to settle all of the forward sale agreements through the delivery of only shares of Class C Common Stock.

The completion of the Depositary Shares Offering is not conditioned upon completion of the Common Stock Offering, and the completion of the Common Stock Offering is not conditioned upon completion of the Depositary Shares Offering.

Morgan Stanley and Goldman Sachs & Co. LLC are acting as lead joint bookrunning managers for the Offerings. Allen & Company LLC, BDT & MSD, Centerview Partners, Jefferies, Lazard, and The Raine Group are acting as co-managers for the Offerings.

A registration statement on Form S-3 (including a prospectus) relating to these securities has been filed with the Securities and Exchange Commission (the "SEC") and has become effective. Each Offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplements and accompanying prospectuses related to the Offerings can be obtained by visiting the SEC's website at http://www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by email at [email protected]; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by email at [email protected].

Celsius Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CELH

NEW YORK, Oct. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Celsius Holdings, Inc. ("Celsius" or "the Company") (NASDAQ: CELH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of CELH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 21, 2025 to June 3, 2026

DEADLINE: November 3, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Celsius marketed Alani Nu drinks to underage consumers despite the potential health risks the products could cause for people under the age of 18. Based on these facts, Celsius' public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

Share this article

Papa John's International, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PZZA

NEW YORK, Oct. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Papa John's International, Inc. ("Papa John's" or "the Company") (NASDAQ: PZZA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of PZZA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 7, 2025 to August 5, 2026

DEADLINE: November 2, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Papa John's continued to lose market share as its transformation plan failed to achieve results as quickly as it had planned. The Company used aggressive promotions to protect its market share. Based on these facts, Papa John's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

Share this article

Dear Duchenne Community,

As we begin the new year, we want to wish you and your families a happy and healthy 2026 and to thank you for your continued partnership. We are writing to share an update on SGT-003, our investigational next-generation gene therapy for Duchenne muscular dystrophy.

Today, we announced that 33 participants have been dosed (ages 1-10, as of January 9, 2026) in INSPIRE DUCHENNE, our Phase 1/2, open-label, multi-center clinical study evaluating the safety, tolerability, and efficacy of SGT-003.

We are proud to stand in partnership with the Duchenne community and remain committed to sharing timely, transparent safety information for every participant who receives SGT-003 so families and clinicians can make informed decisions. That openness and accountability are core to how we conduct this program. As of the January 9, 2026, cutoff, SGT-003 has been generally well tolerated using prophylactic steroids alone for immune suppression. No cases of drug-induced liver injury (DILI), thrombotic microangiopathy (TMA), atypical hemolytic uremic syndrome (aHUS) or myocarditis have been observed. Cardiac monitoring has shown consistent reductions in markers of cardiac injury with early signals of normalization, and we have observed compelling microdystrophin expression and improvements across multiple biomarkers of muscle health. Additional information may be found in a company press release issued today.

The unmet need in Duchenne remains high, and we feel a deep responsibility in advancing SGT-003. To support the path forward, we are pursuing an integrated U.S. and ex-U.S. pivotal trial strategy to support potential accelerated regulatory authorizations. We are pleased to share that we have enrolled the first patient in IMPACT DUCHENNE, our Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy of SGT-003, and expect to initiate dosing in the first quarter of this year. As previously announced, IMPACT DUCHENNE will be conducted outside the United States. The first clinical trial sites have been activated in Canada and Australia, and we plan to expand to European countries beginning mid-year 2026, subject to receipt of regulatory approvals.

We would like to express our sincere gratitude to the patients and families who choose to participate in clinical research. We recognize the time, energy, trust, and courage these decisions require, and we are deeply thankful for the partnership and commitment families bring to advancing the field for the entire Duchenne community.

We remain committed to sharing updates clearly and in a timely manner. The most up-to-date information for both clinical studies may be found on ClinicalTrials.gov.

- INSPIRE DUCHENNE (NCT06138639)

- IMPACT DUCHENNE (NCT07160634)

An additional resource for our ongoing research may be found here: https://www.solidbio.com/patient-caregiver-resources/resources-policies/clinical-trials

We are looking forward to connecting with the Duchenne community in person in the coming months, including at:

- Duchenne UK’s New Horizons Conference, February 6–7 in London, U.K.

- Parent Project’s 23rd Annual International Duchenne and Becker Conference, February 27–March 1 in Rome, Italy

If you have questions or would like to be in touch, please reach out to our patient advocacy team at community@solidbio.com.

Thank you again for your trust and partnership.

With gratitude,

Annie Ganot

Co-founder, SVP Patient Advocacy

Solid Biosciences

The EBA is an independent EU Authority. We play a key role in safeguarding the integrity and robustness of the EU banking sector to support financial stability in the EU.

To contribute to the stability and effectiveness of the European financial system, the EBA develops harmonised rules for financial institutions, promotes convergence of supervisory practices, monitors, and advises on the impact of financial innovation and the transition to sustainable finance.

To ensure the orderly functioning and stability of the financial system in the European Union, we monitor and analyse risks and vulnerabilities relevant for the regulation of banks and investment firms. We also facilitate information sharing among authorities and institutions through supervisory reporting and data disclosure.

Communicating to all our audiences in the most effective way and using the most appropriate channels is crucial for us. Through our publications, announcements, and participation in external events, we are committed to reaching out to all our stakeholders to report about our policies, activities, and initiatives.

Skip to main content

User account menu

Log In

Engage

Join

Shop

Subscribe

Suppliers

Jobs

Contact

My Account

Powering Strong Communities

Main navigation

About

About

The Association

Value of APPA

Members

Member Directory

JAAs & State Associations

Corporate Associate Members

Join

Leadership & Board

Careers with APPA

Newsroom

Public Power

What Is Public Power?

Where Is Public Power?

Stats and Facts

Electricity Basics

Forming a Public Power Utility

Promoting Public Power

Protecting Public Power

Utility Jobs

Issues & Policy

Issues & Policy

Key Issues

Maintain Affordability

Electric Reliability

Permitting Reform

Mitigate Wildfires

Supporting FEMA

Regulatory

Energy Regulation Filings

Environment Filings

Take Action

Resolutions

PowerPAC

Legislative Rally

Policy Makers Council

Programs & Services

Programs & Services

Energy Innovation

Grants and Scholarships

Research and Development

Grid Security

Cyber and Physical Security

Cybersecurity Accelerator Program

Mutual Aid and Emergency Response

Wildfire Mitigation Planning

Risk Management

Benchmarking & Operations

Reliable Public Power Provider

Smart Energy Provider

PowerTRX Reliability

Safety

PowerTRX Safety

Surveys and Survey Reports

Utility Operational Excellence Guide

Awards

APPA Academy

APPA Academy

In-Person Events

Customer Connections Conference

Joint Action Conference

Online Events

Courses & Webinars

On-Demand Library

Events Calendar

Coaching & Advisory Services

Sponsor & Exhibit

In-House Training

News

News

Public Power Current newsletter

Public Power Magazine

Podcasts

Advertising

Newsroom

For Members

For Members

Member Welcome Center

Utility Member Benefits Quick Reference

Utility Member Handbook

Featured Products

CEERUM Energy Planning Tool

Monster Detective Collective

PowerTRX Pro

Public Power Data Source

Resources

Artificial Intelligence

Awards

Data Centers

DEED R&D

Energy Tax Credits for Utilities

Governance

Member Directory

Mutual Aid/Emergency Response

Promoting Public Power

Utility Operational Excellence Guide

Surveys & Survey Reports

APPA Engage

Vendor Opportunities: RFP Portal

User account menu

Log In

Engage

Join

Shop

Subscribe

Suppliers

Jobs

Contact

My Account

Search

You are here

Home

Break

Mon, 02/08/2027 - 10:00

Mon, 02/08/2027 - 10:15

You are about to review presentations, reports and/or filings of SBC Medical Group Holdings, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. SBC Medical Group Holdings, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by SBC Medical Group Holdings, Inc.

I Accept I Decline

You are about to review presentations, reports and/or filings of SBC Medical Group Holdings, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. SBC Medical Group Holdings, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by SBC Medical Group Holdings, Inc.

I Accept I Decline